Shares of InMode Ltd INMD are trading lower Monday morning after the Israeli medical technology company said a special ...

InMode Ltd. is rated a Strong Buy due to its robust balance sheet, proprietary technology, and international growth. Learn more about INMD stock here.

InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today ...

InMode’s products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share ...

InMode Ltd. (NASDAQ:INMD) Q4 2025 Earnings Call Transcript February 10, 2026 InMode Ltd. beats earnings expectations.

Good day, and welcome to the InMode fourth quarter and full year 2024 earnings results conference call. [Operator instructions] Please note, this event is being recorded. I would now like to turn the ...

Despite the quarterly beat, InMode’s stock declined after the company issued full-year 2026 guidance below Wall Street expectations. The company forecasts adjusted earnings of $1.43 to $1.48 per share ...

Interested investors are welcome to contact their BTIG salesperson and schedule a meeting. For more information about the event, visit InMode's investor relations site here.

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...

Good day, and welcome to InMode's second quarter 2024 earnings results conference call. All participants will be in listen-only mode. [Operator instructions]. After today's presentation, there will be ...

Thank you, Miri, and to everyone for joining us. With me today are Dr. Michael Crindel, our Co-Founder and Chief Technology Officer, Yair Malca, our Chief Financial Officer, and Rafael Liqueman, our ...